Maxcyte (MXCT) Gains from Investment Securities (2019 - 2026)
Maxcyte has reported Gains from Investment Securities over the past 7 years, most recently at -$155000.0 for Q4 2025.
- Quarterly Gains from Investment Securities fell 132.22% to -$155000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547000.0 through Dec 2025, up 56.39% year-over-year, with the annual reading at $2.6 million for FY2025, 81.69% down from the prior year.
- Gains from Investment Securities was -$155000.0 for Q4 2025 at Maxcyte, down from $554938.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $24.8 million in Q4 2021 and troughed at -$231000.0 in Q4 2023.
- The 5-year median for Gains from Investment Securities is $554938.0 (2025), against an average of $2.7 million.
- Year-over-year, Gains from Investment Securities soared 41653.51% in 2021 and then plummeted 273.99% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $24.8 million in 2021, then plummeted by 99.47% to $132763.0 in 2022, then plummeted by 273.99% to -$231000.0 in 2023, then surged by 308.23% to $481000.0 in 2024, then crashed by 132.22% to -$155000.0 in 2025.
- Per Business Quant, the three most recent readings for MXCT's Gains from Investment Securities are -$155000.0 (Q4 2025), $554938.0 (Q2 2025), and $254000.0 (Q1 2025).